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Novel synthetic opioids (NSO) are increasingly encountered in illicit heroin and counterfeit pain pills.
Many NSO are resurrected from older biomedical literature or patent applications, so limited information
is available about their biological effects. Here we examined the pharmacology of three structurally-
distinct NSO found in the recreational drug market: N-(1-(2-phenylethyl)-4-piperidinyl)-N-phenyl-
butyramide (butyrylfentanyl), 3,4-dichloro-N-[(1R,2R)-2-(dimethylamino)cyclohexyl]-N-methyl-
benzamide (U-47700) and 1-cyclohexyl-4-(1,2-diphenylethyl)piperazine (MT-45). Radioligand binding
and GTPgS functional assays were carried out in cells transfected with murine mu- (MOR-1), delta- (DOR-
1) or kappa-opioid receptors (KOR-1). Antinociceptive effects were determined using the radiant heat tail
flick technique in mice, and opioid specificity was assessed with the mu-opioid antagonist naloxone.
Butyrylfentanyl, U-47700 and MT-45 displayed nM affinities at MOR-1, but were less potent than
morphine, and had much weaker effects at DOR-1 and KOR-1. All NSO exhibited agonist actions at MOR-1
in the GTPgS assay. Butyrylfentanyl and U-47700 were 31- and 12-fold more potent than morphine in the
tail flick assay, whereas MT-45 was equipotent with morphine. Analgesic effects were reversed by
naloxone and absent in genetically-engineered mice lacking MOR-1. Our findings confirm that butyr-
ylfentanyl, U-47700 and MT-45 are selective MOR-1 agonists with in vitro affinities less than morphine.
However, analgesic potencies vary more than 30-fold across the compounds, and in vitro binding affinity
does not predict in vivo potency. Taken together, our findings highlight the risks to humans who may
unknowingly be exposed to these and other NSO when taking adulterated heroin or counterfeit pain
medications.1. Introduction
New psychoactive substance (NPS) are synthetic alternatives toenkephalin; DPDPE, [D-Pen2,
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umann).more traditional drugs of abuse, specifically engineered to
circumvent existing drug control laws (Madras, 2017). The emer-
gence of NPS is a global phenomenon fueled by the growth of
internet commerce and manufacturing capacity of Asian countries
(Brandt et al., 2014). More than 600 different NPS have been
identified worldwide by the United Nations Office of Drugs and
Crime since 2008 (United Nations Office of Drugs and Crime, 2016).
While synthetic stimulants and cannabinoids are the most com-
mon types of NPS, an increasing number of synthetic opioids are
being encountered in the recreational (i.e., non-medical) drug
market in the United States (US) and elsewhere (Prekupec et al.,
2017). Novel synthetic opioids (NSO) include various fentanyl an-
alogs and non-fentanyl compoundswhich exhibit agonist actions at
mu-opioid receptors (MOR-1)(see Fig. 1 for chemical structures).
Fentanyl is a prescribed medication that is 50- to 100-times more
potent thanmorphine (Suzuki and El-Haddad, 2017; Vuckovic et al.,
2009), but most fentanyl in the recreational drug market is man-
ufactured by Chinese laboratories and trafficked via the internet,
much like other NPS (US-China Economic and Security Review
Commission, 2017). At present, the US is experiencing an
epidemic of opioid-related overdose deaths, and this crisis is being
exacerbated by the prevalence of fentanyl and NSO in products sold
as heroin or pain medications (Gladden et al., 2016; Green and
Gilbert, 2016; Rudd et al., 2016).
Recent data from law enforcement agencies in the US show that
illicitly manufactured fentanyl is the predominant synthetic opioid
confiscated (e.g., Drug Enforcement Administration, 2016a). How-
ever, many fentanyl analogs and structurally-distinct non-fentanyl
opioid receptor agonist are being encountered, and this trend is
expected to continue (Prekupec et al., 2017). Butyrylfentanyl is an
example of a fentanyl analog that has appeared in the recreational
drug marketplace as a heroin adulterant (Drug Enforcement
Administration, 2016b). Butyrylfentanyl was first mentioned in
the scientific literature during the 1980s and is reportedly 7-fold
more potent than morphine in the mouse acetic acid writhing
assay (Higashikawa and Suzuki, 2008; Woods et al., 1988). A
number of opioid-related overdose deaths have been attributed to
butyrylfentanyl and are documented in the forensic literature
(McIntyre et al., 2016; Poklis et al., 2016). U-47700 is an example of
a non-fentanyl benzamide compound that has emerged as a heroin
adulterant and constituent of counterfeit pain pills (Armenian et al.,
2017; Drug Enforcement Administration, 2016c). U-47700 was
originally investigated as an analgesic agent by the Upjohn Com-
pany in the late 1970s and is 8-fold more potent than morphine in
mouse antinociception assays (Cheney et al., 1985; Szmuszkowicz
and inventor, 1978). U-47700 served as an important lead com-
pound in the development of selective kappa-opioid agonists like
2-(3,4-dichlorophenyl)-N-methyl-N-[(1R,2R)-2-pyrrolidin-1-
ylcyclohexyl]acetamide (U50,488). U-47700 has been implicated in
a number of recent overdose deaths (Elliott et al., 2016; Mohr et al.,Fig. 1. Chemical structures of novel synthetic opioids (NSO) as compared to heroin and
morphine. U-47700 is 3,4-dichloro-N-[(1R,2R)-2-(dimethylamino)cyclohexyl]-N-
methylbenzamide whereas MT-45 is 1-cyclohexyl-4-(1,2-diphenylethyl)piperazine.2016). MT-45 is a non-fentanyl compound first developed by the
Dainippon Pharmaceutical Company in the 1970s as an analgesic
agent (Nishimura et al., 1976). While MT-45 is rarely encountered in
the US, the compound has been associated with multiple deaths in
European countries (EMCDDA, 2014; Siddiqi et al., 2015).
The widespread availability of compounds like butyrylfentanyl,
U-47700 and MT-45 represents a serious public health concern,
because humans are often unknowingly exposed to these agents
(Amlani et al., 2015; Drug Enforcement Administration, 2016d).
Additionally, there is little up-to-date information about the bio-
logical effects of these drugs, most of which were studied decades
ago using diverse in vitro and in vivo research approaches that are
now replaced by newer methods (Suzuki and El-Haddad, 2017;
Prekupec et al., 2017). In particular, the cloning of opioid receptor
genes has enabled the generation of cell lines expressing pure
populations of opioid receptor subtypes, and the generation of
genetically-engineered mice lacking these same receptors. There-
fore, the purpose of the present study was to carry out a side-by-
side comparison of the pharmacology of NSO and the prototypi-
cal mu agonist morphine, using standard opioid-related assay
methods. We examined the effects of butyrylfentanyl, U-47700 and
MT-45 in radioligand binding and GTPgS functional assays in cells
transfected with mouse MOR-1, delta-opioid receptors (DOR-1) or
kappa-opioid receptors (KOR-1) (Bolan et al., 2004). Broad recep-
torome screening was carried out to identify potential non-opioid
sites of action (Kroeze et al., 2015). Antinociceptive effects of the
drugs were determined using the radiant heat tail flick assay in
mice, and opioid specificity was evaluated using naloxone pre-
treatment (Majumdar et al., 2011b). Tail flick assays were also car-
ried out in genetically-engineered knock out (KO) mice lacking
specific splice variants of MOR-1 (Lu et al., 2015; Pan et al., 2009).
2. Materials and methods
2.1. Drugs and chemicals
N-(1-(2-Phenylethyl)-4-piperidinyl)-N-phenylbutyramide HCl
(butyrylfentanyl), 3,4-dichloro-N-[(1R,2R)-2-(dimethylamino)
cyclohexyl]-N-methylbenzamide (U-47700) and 1-cyclohexyl-4-
(1,2-diphenylethyl)piperazine 2HCl (MT-45) were obtained as dry
powders from Cayman Chemical (Ann Arbor, MI, USA). For the
in vitro assays, drug powders were diluted in DMSO to yield 10 mM
stocks that were stored frozen; on the day of an experiment, stock
solutions were thawed and diluted in assay buffer. For the in vivo
analgesia tests, powdered butyrylfentanyl and MT-45 were diluted
in sterile water to yield the desired doses. U-47700 was diluted in
sterile water with 0.25% HCl. 3-Iodobenzoylnaltrexamine (IBNtxA)
and [125I]IBNtxA were synthesized in our laboratory as previously
described (Majumdar et al., 2011a). Na125I and [35S]GTPgS were
purchased from PerkinElmer (Waltham, MA, USA). [D-Ala2,N-
MePhe4,Gly-ol]-enkephalin (DAMGO), [D-Pen2, D-Pen5]-enkeph-
alin (DPDPE), (±)-2-(3,4-dichlorophenyl)-N-methyl-N-[(1R,2R)-2-
pyrrolidin-1-ylcyclohexyl]acetamide HCl (U-50,488) and naloxone
were generously provided by the National Institute on Drug Abuse
(NIDA), Drug Supply Program (Rockville, MD, USA). All other
chemicals and reagents were purchased from Sigma-Aldrich (St
Louis, MO, USA).
2.2. Animals
Male CD1 mice (20e32 g) were obtained from Charles River
Laboratories (Frederick, MD, USA), while male C57BL/6 J mice
(20e32 g) were obtained from Jackson Laboratories (Bar Harbor,
ME, USA). Exon-1/exon-11 MOR-1 knockout (E1/E11 KO) mice
which lack expression of all Oprm1 splice variants were bred on a
mixed C57BL/6 J/129Sv6 background in the animal facility at Me-
morial Sloan Kettering Cancer Center (MSKCC). Similarly, exon-11
KO (E11 KO) mice, which lack 6-transmembrane splice variants of
MOR-1, were bred on a C57BL/6 J background. All micewere housed
in groups of five and maintained on a 12 h light/dark cycle with
food andwater available ad libitum. Experiments were approved by
the Institutional Animal Care and Use Committee of the MSKCC in
accordance with the 2002 National Institutes of Health Guide for
the Care and Use of Laboratory Animals. All mice used for these
experiments were opioid naïve at the time of drug treatments.2.3. Radioligand binding assays
[125I]IBNtxA (0.1 nM) competition binding assays were per-
formed in membranes prepared from Chinese Hamster Ovary
(CHO) cells stably expressing mouse MOR-1, DOR-1 or KOR-1, as
previously described (Varadi et al., 2013, 2015). Binding was per-
formed at 25 C for 90min. Binding inMOR-1/CHO cells was carried
out in 50 mM potassium phosphate buffer with 5 mM MgSO4 and
20 mg/mL protein, while binding in DOR-1/CHO and KOR-1/CHO
cells was carried out in 50 mM potassium phosphate buffer and
20 mg/mL protein. Eight different concentrations of butyrylfentanyl,
U-47700 or MT-45 were tested to create dose-response inhibition
curves. After the incubation, the reaction was rapidly filtered
through glass fiber filters (Whatman Schleicher & Schuell, Keene,
NH, USA) and washed three times with 3 mL of ice-cold 5 mM Tris-
HCl, pH 7.4, on a semiautomatic cell harvester (Brandel, Gaithers-
burg, MD, USA). Nonspecific binding was defined in the presence of
levallorphan (8 mM) and was subtracted from total binding to yield
specific binding. Ki values were calculated by nonlinear regression
analysis using commercially-available software (GraphPad Prism,
San Diego, CA, USA). Protein concentrations were determined using
the Lowry method. The compounds were also tested by the Psy-
choactive Drug Screening Program (PDSP) of the National Institute
of Mental Health (NIMH) to interrogate binding activity at 300
different G protein-coupled receptors, as a means to identify po-
tential non-opioid sites of action (Kroeze et al., 2015).Table 1













Morphine 5.0 ± 0.6 N.D. N.D. 3.5 ± 0.8
Butyrylfentanyl 18 ± 5 286 ± 56 3174 ± 410 18 ± 2
U-47700 57 ± 21 1105 ± 223 653 ± 163 39 ± 4
MT-45 44 ± 17 606 ± 19 204 ± 15 44 ± 6
[125I]IBNtxA binding was carried out in cells expressing MOR-1, DOR-1 or KOR-1 as
described in Materials and Methods. Data are mean ± SEM for N ¼ 3 experiments
performed in triplicate. N.D. indicates not determined. * Comparator MOR-1 data
obtained from NIMH Psychoactive Drug Screening Program (PDSP) using [3H]
DAMGO as the tritiated ligand. Information about assay methods can be found at
http://pdsp.med.unc.edu/pdsp/binding.php.2.4. [35S]GTPgS functional assays
[35S]GTPgS binding was performed on membranes prepared
from transfected cells stably expressing opioid receptors as previ-
ously described (Bolan et al., 2004; Varadi et al., 2015). Briefly, in-
cubations were carried out for 60 min at 30 C in assay buffer
(50 mM Tris-HCl, pH 7.4, 3 mM MgCl2, 0.2 mM EGTA, and 100 mM
NaCl), containing 0.05 nM [35S]GTPgS; 20 mg/mL each leupeptin,
pepstatin, aprotinin, and bestatin; and 30 mM GDP. Eight different
concentrations of butyrylfentanyl, U-47700 or MT-45 were tested
to create dose-response curves. After the incubation, the reaction
was rapidly filtered through glass fiber filters (Whatman Schleicher
& Schuell, Keene, NH, USA) and washed three times with 3 mL of
ice-cold buffer (5 mM Tris-HCl, pH 7.4) on a semiautomatic cell
harvester. Filters were transferred into vials with 3 mL of Liquiscint
(National Diagnostics, Atlanta, GA, USA), and the radioactivity in
vials was determined by scintillation spectroscopy in a Tri-Carb
2900 TR counter (PerkinElmer Life Sciences, Shelton, CT, USA).
Basal binding was determined in the presence of GDP and the
absence of drug. EC50 and %Emax values were calculated by
nonlinear regression analysis using commercially-available soft-
ware (GraphPad Prism, San Diego, CA, USA). EC50 is the drug con-
centration eliciting 50% of maximal response (%Emax), which is
defined by the effects of 100 nMDAMGO, DPDPE or U50-488 for the
MOR-1, DOR-1 or KOR-1 assays, respectively.2.5. Antinociception testing
Tail flick antinociceptionwas determined by the radiant heat tail
flick technique using an Ugo Basile model 37360 instrument, as
previously described (Varadi et al., 2015). The intensity was set to
achieve a baseline response between 2 and 3 s. Baseline latencies
were determined before experimental treatments for all mice, and
a maximal 10 s latency was used to minimize damage to the tail.
Raw data were transformed to percent maximal effect, %MPE,
whichwas calculated according to the formula: %MPE¼ [(observed
latency e baseline latency)/(maximal latency  baseline
latency)]  100. Compounds were injected subcutaneously (s.c.)
and antinociception was assessed 15 min later at the peak effect.
Dose-response experiments were first assessed in CD1 mice to
determine EC50 values, which were calculated using commercially-
available software (GraphPad Prism, San Diego, CA, USA). For the
antagonism studies, 1 mg/kg naloxone was administered 15 min
before the agonist agent. Additional antinociception testing was
carried out in E1/E11 KO mice, which lack all mu receptor gene
expression, to confirm mu-opioid specificity of the observed ef-
fects. Finally, drugs were tested for antinociceptive actions in E11
KOmice to identify potential contributions of different sets of splice
variants (Majumdar et al., 2011b; Pan et al., 2009).3. Results
3.1. Results from in vitro binding methods
Table 1 summarizes the results for displacement of [125I]IBNtxA
binding in CHO cells expressing mouse MOR-1, DOR-1 and KOR-1.
Butyrylfentanyl, U-47700 and MT-45 displayed similar mu-
selective effects on binding, with Ki values ranging from 18 to
57 nM at MOR-1. Butyrylfentanyl and U-47700 had at least 10-fold
greater affinity for MOR-1 when compared to their effects at DOR-1
and KOR-1.MT-45was somewhat lessmu-selective, with 13- and 4-
fold greater affinity at MOR-1 versus DOR-1 and KOR-1, respec-
tively. Interestingly, all of the NSO tested were less potent than
morphine at inhibiting [125I]IBNtxA binding to MOR-1. Findings
from the PDSP receptorome screening corroborated our findings in
CHO cells, and demonstrated that butyrylfentanyl, U-47700 and
MT-45 inhibited [3H]DAMGO binding to MOR-1, but the drugs had
muchweaker effects at DOR-1 and KOR-1. No other non-opioid sites
of action were identified for the compounds when tested (10 mM)
across an array of G protein-coupled receptors (data not shown).
Table 2 summarizes the effects of NSO in the [35S]GTPgS func-
tional assay in cells expressing MOR-1, DOR-1 or KOR-1. Consistent
with the radioligand binding results, butyrylfentanyl, U-47700 and
MT-45 acted as selective and efficacious mu-opioid agonists, with
potencies ranging from 43 to 214 nM at MOR-1. U-47700 displayed
Table 2
Functional activities for NSO at opioid receptor subtypes in the GTPgS assay.
Ligand MOR-1 DOR-1 KOR-1
EC50 (nM) %Emax EC50 (nM) %Emax EC50 (nM) %Emax
Butyrylfentanyl 43 ± 5 76 ± 1 910 ± 628 43 ± 5 1236 ± 625 39 ± 1
U-47700 214 ± 23 97 ± 2 5161 ± 1357 62 ± 1 2699 ± 769 53 ± 1
MT-45 124 ± 12 71 ± 7 3250 ± 1074 49 ± 1 inactive inactive
[35S]GTPgS binding was performed in cells expressing MOR-1, DOR-1 or KOR-1 as
described in Materials and Methods. Data are mean ± SEM for N ¼ 3 experiments
performed in triplicate. Potency is measured as EC50 while efficacy is % of maximal
effect (%Emax).full efficacy at MOR-1, while butyrylfentanyl and MT-45 were
somewhat less efficacious as compared to the prototypic MOR-1
agonist DAMGO. All NSO displayed at least 10-fold greater po-
tency at MOR-1 when compared to effects at DOR-1 and KOR-1.
Butyrylfentanyl and U-47700 were weak partial agonists at DOR-
1 and KOR-1, whereas MT-45 was a partial agonist at DOR-1 and
inactive at KOR-1 when compared to the prototypic DOR-1 agonist
DPDPE or KOR-1 agonist U50,488.3.2. Results from in vivo antinociception assays
Fig. 2 depicts the dose-response effects of NSO and morphine in
the radiant heat tail flick assay in male CD1 mice. All compounds
evoked dose-dependent and efficacious antinociceptive actions
with the rank order of potency: butyrylfentanyl > U-47700 > MT-
45 ¼ morphine. Table 3 shows potency estimates for the com-
pounds, expressed as EC50 values, and demonstrates that butyr-
ylfentanyl (EC50 ¼ 0.08 mg/kg, s.c.) was 31-fold more potent than
morphine (EC50 ¼ 2.5 mg/kg, s.c.) while U-47700 (EC50 ¼ 0.21 mg/
kg, s.c.) was 12-fold more potent than morphine in vivo.
Fig. 3 shows the time-course of antinociceptive effects for NSO
as compared to morphine in CD1 mice. The time of peak anti-
nociception activity was similar across the compounds after s.c.
administration, but butyrylfentanyl (0.2 mg/kg) and U-47700
(0.75 mg/kg) had more transient effects than MT-45 (5 mg/kg) and
morphine (4.5 mg/kg). Fig. 4 depicts the effects of naloxone pre-
treatment on antinociceptive effects of NSO and morphine.
Administration of 1 mg/kg s.c. naloxone completely blocked the
antinociceptive effects of s.c. butyrylfentanyl (0.2 mg/kg), U-47700
(0.75 mg/kg), MT-45 (5 mg/kg) and morphine (4.5 mg/kg), con-
firming the opioid specificity of the observed actions.
Fig. 5 depicts analgesic actions of NSO in mice lacking exon-1
and exon-11 variants of MOR-1 (E1/E11 KO) and their wildtype
counterparts (mixed C57/BJ6/129Sv6). Table 3 summarizes EC50
values. All three NSO showed loss of analgesic actions in E1/E11 KOFig. 2. Cumulative dose-response effects for morphine and NSO in the radiant heat tail
flick assay carried out in CD1 mice. Morphine, butyrylfentanyl, U-47700 or MT-45 were
administered s.c. and tail flick assays were carried out as described in Materials and
Methods. Data are mean ± SEM for N ¼ 6 mice per group, expressed as percentage of
maximal possible effect (%MPE). Experiments were replicated twice with similar
results.mice, confirming MOR-1 as the primary target of action for these
drugs. We also investigated the effects of NSO in mice lacking the
exon-11 MOR-1 splice variants (E11 KO), since we have previously
shown this receptor variant is involved in analgesic actions of
certain compounds (Majumdar et al., 2011b; Pan et al., 2009;
Grinnell et al., 2016). As shown in Fig. 6 and summarized in
Table 3, the effects of NSO were less potent in C57BL/6 J WT mice
when compared to their effects in CD1 mice, but there were no
significant differences in antinociceptive potencies between E11 KO
mice and their C57/B6JWTcounterparts. The datawith E11 KOmice
confirm that NSO display antinociceptive actions via a mechanism
analogous to morphine, which retains full analgesic activity in the
E11 KO mice (Pan et al., 2009; Marrone et al., 2017).
4. Discussion
The US is currently experiencing an epidemic of opioid-related
overdose deaths, and this phenomenon is exacerbated by the
increasing availability of illicitly manufactured fentanyl in the rec-
reational drugmarketplace (Frank and Pollack, 2017; Gladden et al.,
2016; Rudd et al., 2016). A disturbing new trend in this regard is the
emergence of structurally-diverse NSO as standalone products,
adulterants in illicit heroin or constituents of counterfeit pain
medications (Drug Enforcement Administration, 2016a; Prekupec
et al., 2017). Most NSO are resurrected from older biomedical
literature or patent applications, so there is scant information about
their biological effects (Suzuki and El-Haddad, 2017). Thus, the
purpose of the present investigation was to examine the pharma-
cological effects of three commonly encountered NSO as compared
to the prototypical mu-opioid agonist morphine. We found that
butyrylfentanyl, U-47700 and MT-45 act as selective MOR-1 ago-
nists in vitro, but binding affinities for the compounds do not pre-
dict their analgesic potencies in vivo. Importantly, butyrylfentanyl
and U-47700 are 31- and 12-fold more potent than morphine as
analgesic agents in vivo, suggesting these compounds and their
structural analogs could pose significant public health risks,
including the possibility of fatal overdose (see Elliott et al., 2016;
McIntyre et al., 2016; Mohr et al., 2016; Poklis et al., 2016).
Our radioligand binding results with butyrylfentanyl, U-47700
and MT-45 represent the first investigation of the compounds in
cells transfected with MOR-1, DOR-1 and KOR-1. Prior literature has
reported effects of the drugs in receptor binding assays using brain
tissue from rats or guinea pigs, and a variety of tritiated ligands
(Alburges et al., 1992; Cheney et al., 1985; Fujimura et al., 1978;
Loew et al., 1988). We found that butyrylfentanyl, U-47700 and
MT-45 display Ki values at MOR-1 ranging from 18 to 57 nM (see
Table 1), whereas the drugs havemuchweaker effects on binding at
DOR-1 and KOR-1. Our results with butyrylfentanyl agree with
those of Alburges et al. (1992) who showed the compound inhibits
binding of [3H]fentanyl in rat brain tissue with an IC50 of 32 nM.We
observed that U-47700 displays a Ki of 57 nM at mu-opioid re-
ceptors, but prior studies report a broad range of affinity values. For
example, Cheney et al. (1985) found that U-47700 exhibits a Ki of
110 nM for inhibiting [3H]naloxone binding in rat brain, whereas
Loew et al. (1988) found a Ki of 5 nM for inhibiting [3H]DAMGO in
guinea pig brain. The Ki of MT-45 that we observed for inhibition of
opioid agonist binding is indicative of greater potency than re-
ported previously for inhibition of opioid antagonist binding.
Fujimura et al. (1978) and Nozaki et al. (1983) both demonstrated
that MT-45 inhibits [3H]naloxone binding to mu receptors in rat
brain tissue with an IC50 of about 700 nM. It seems probable that
discrepancies in mu receptor binding affinities across studies are
related to different assay methods and radioligands employed,
though the present data show that structurally-distinct NSO exhibit
similar binding affinities at MOR-1 when labeled with either [125I]
Table 3











































Tail flick antinociception was carried out as described in Materials and Methods. Data are mean ± 95% confidence intervals for N ¼ 5e6 mice per group. Experiments were
replicated twice with similar results. Potency is measured as EC50. N.D. is not determined, while ‘inactive’ indicates no antinociceptive activity.
Fig. 3. Time-course effects for morphine and NSO in the radiant heat tail flick assay
carried out in CD1 mice. Mice received s.c. morphine (4.5 mg/kg), butyrylfentanyl
(0.2 mg/kg), U-47700 (0.75 mg/kg) or MT-45 (5 mg/kg). Tail flick responses were
monitored up to 180 min post-injection. Data are mean ± SEM for N ¼ 6 mice per
group, expressed as percent of maximal possible effect (%MPE). Experiments were
replicated twice with similar results.
Fig. 4. Effects of naloxone on antinociception produced by morphine and NSO in CD1
mice. Mice received s.c. naloxone (NLX, 1 mg/kg) or saline vehicle (VEH) 15 min prior to
injection of morphine (Morph, 4.5 mg/kg), butyrylfentanyl (Butyr, 0.2 mg/kg), U-47700
(U-477, 0.75 mg/kg) or MT-45 (5 mg/kg). Data are mean ± SEM, expressed as percent
maximal possible effect (%MPE) at the time of peak analgesic effect.BNtxA or [3H]DAMGO. Overall, our binding results from CHO cells
and receptorome screening methods show that all NSO tested
display less affinity for MOR-1 when compared to the prototypical
mu-opioid agonist morphine.
The [35S]GTPgS binding assay is used to assess functional
coupling between opioid receptor binding events and intracellular
transduction pathways, thereby providing an index of drug efficacy
(Selley et al., 1997). To the best of our knowledge, the presentfindings are the only data available for effects of butyrylfentanyl, U-
47700 and MT-45 in the GTPgS assay. We show that all three NSO
are efficacious agonists at MOR-1 with potencies ranging from 43 to
214 nM (see Table 2), while the drugs have much weaker effects at
DOR-1 and KOR-1. Our data agree with older literature demon-
strating opioid agonist activity for butyrylfentanyl andMT-45 using
in vitro preparations such as guinea pig ileum or mouse vas defer-
ens (Fujimura et al., 1978; Woods et al., 1988), where opioid ago-
nists induce inhibition of electrically-evoked smooth muscle
contractions (Hayes et al., 1985). Woods et al. (1988) showed that
butyrylfentanyl displays an IC50 of 442 nM for inhibiting muscle
contractions in the mouse vas deferens, whereas Fujimura et al.
(1978) showed MT-45 has an IC50 of 15 nM in the guinea pig
ileum assay. We found that MT-45 exhibits an unusual profile of
functional activity at opioid receptor subtypes, acting as an effica-
cious agonist at MOR-1, a weak partial agonist at DOR-1, while
being inactive at KOR-1 (see Table 2). It is tempting to speculate that
the unique in vitro pharmacology of MT-45 might underlie its un-
usual clinical side-effects which include a deep level of uncon-
sciousness, ototoxicity, hair loss and dermatitis (Helander et al.,
2014, 2017).
The ability of MOR-1 agonists to induce antinociception in ro-
dent models is a valid predictor of pain relief, and other opioid-
mediated effects, in clinical settings (Pasternak, 2014). Here we
demonstrate that butyrylfentanyl, U-47700 and MT-45 act as
MOR-1 agonists in vivo and induce efficacious analgesic actions
similar to the effects of morphine. Importantly, butyrylfentanyl
and U-47700 are 31- and 12-fold more potent than morphine in
the mouse radiant heat tail flick test (see Fig. 2 and Table 3). The
present in vivo results agree qualitatively with previous findings
examining the analgesic effects of NSO studied here, but there are
noteworthy differences in drug potency versus effects of
morphine. Higashikawa and Suzuki (2008) reported that orally
administered butyrylfentanyl and morphine display EC50 values of
0.05 and 0.33 mg/kg for analgesic activity in the mouse acetic acid
writhing assay, indicating butyrylfentanyl is 7-fold more potent
than morphine. By contrast, we found that s.c. administered
butyrylfentanyl is 31-fold more potent than morphine in the tail
flick assay. Cheney et al. (1985) showed that s.c. administered U-
47700 and morphine have EC50 values of 0.2 and 1.5 mg/kg for
analgesic activity in the mouse tail flick assay, indicating U-47700
is 7.5-fold more potent than morphine. We found that U-47700 is
12-fold more potent than morphine in an assay system similar to
the one employed by Cheney and coworkers. Our in vivo data
show that MT-45 and morphine have nearly identical analgesic
potency, and this observation agrees with the work of Natsuka
et al. (1975) who found that MT-45 exhibits similar potency to
morphine in the mouse phenylquinone writhing assay and tail
flick test in mice. Finally, we demonstrate that pretreatment with
Fig. 5. Cumulative dose-response effects for NSO in the radiant heat tail flick assay carried out in mixed C57/BJ6/129Sv6 wild type (C57/129 WT) mice and those lacking exon-1 and
exon-11 variants of MOR-1 (E1/E11 KO). Butyrylfentanyl, U-47700 or MT-45 were administered s.c. and tail flick assays were performed as described in Materials and Methods. Data
are mean ± SEM for N ¼ 5 mice per group, expressed as percentage of maximal possible effect (%MPE).
Fig. 6. Cumulative dose-response effects for NSO in the radiant heat tail flick assay carried out in C57BL/6 J WT mice and those lacking the exon-11 MOR-1 splice variant (E11 KO).
Butyrylfentanyl, U-47700 or MT-45 were administered s.c. and tail flick assays were carried out as described in Materials and Methods in either wild-type C57BL/6 J mice or E11 KO
mice. Data are mean ± SEM for N ¼ 5 mice per group, expressed as percentage of maximal possible effect (%MPE).the mu-opioid antagonist naloxone is capable of completely
reversing the antinociceptive effects of butyrylfentanyl, U-47700
and MT-45.
To further explore the role of MOR-1 in mediating the in vivo
effects of NSO, we examined the antinociceptive effects of the drugs
in genetically-engineered mice lacking specific splice variants of
MOR-1. In E1/E11 KO mice lacking all mu-opioid receptor gene
expression, butyrylfentanyl, U-47700 and MT-45 failed to elicit
antinociceptive effects when compared to their WT counterparts.
We also tested effects of the drugs in E11 KO mice, which lack 6-
transmembrane MOR-1 splice variants, since prior evidence
shows that effects of certain opioid agonists (e.g., buprenorphine)
are greatly reduced in this genotype, while morphine retains full
activity. In E11 KO mice, all of the drugs displayed analgesic po-
tencies that were nearly identical to their WT counterparts, sug-
gesting no role for the E11 splice variant in the effects observed.
Collectively, the total loss of analgesia in E1/E11 KO mice, coupled
with the normal analgesic effects in E11 KO mice, confirm that the
three NSO tested act through traditional, full length mu receptors,
in a manner analogous to morphine.
To summarize, we demonstrate that three commonly encoun-
tered NSO are efficacious MOR-1 agonists as determined in vitro
and in vivo. In general, the present findings support older pre-
clinical literature describing the pharmacology of butyrylfentanyl,
U-47700 and MT-45 in rodent models. However, we show that
in vitro binding affinities and functional activities for the drugs do
not predict in vivo analgesic potencies. Stated more simply,
butyrylfentanyl and U-47700 exhibit lower affinity than morphine
at MOR-1 yet are much more potent than morphine in the mouse
tail flick test. One plausible reason for the greater-than-predicted
analgesic potencies for butyrylfentanyl and U-47700 could be
their enhanced brain penetration owing to higher lipophilicity.Morphine is a moderately polar molecule (clogP ¼ 0.57), but
butyrylfentanyl (clogP 4.15) and U-47700 (clogP 4.09) are signifi-
cantly more hydrophobic based on physiochemical predictions.
Other possibilities for the disconnect between in vitro and in vivo
potencies might be related to differences in intrinsic efficacy or
cell-signal amplification across the various drugs tested. Whether
our findings in mice can be extrapolated to the effects of the drugs
in humans is uncertain, but the data illustrate the potential risks to
humans who are unknowingly exposed to NSO as adulterants in
illicit heroin or constituents of counterfeit pain pills (Armenian
et al., 2017; Gladden et al., 2016; Mohr et al., 2016; Rudd et al.,
2016). Another critical question is whether antinociceptive po-
tency estimates can be related to dangerous side-effects such as
respiratory depression and lethality. With respect to fentanyl and
its analogs, it appears that potency from antinociceptive assays in
mice can be used to predict potency of drugs to induce adverse
effects in this species (Suzuki and El-Haddad, 2017; Vuckovic et al.,
2009). Given the rapid pace at which new NSO are entering the
recreational drug market, it seems prudent to carry out more
preclinical research with the drugs to determine their adverse
effects such as abuse liability, tolerance development, and
lethality. The findings from such studies will inform clinicians,
forensic scientists, law enforcement personnel and policymakers
who are involved with responding to the current opioid overdose
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